Boston Scientific Corporation (NYSE: BSX) has had a busy month, and March 2018 isn’t over yet. On March 5, the medical device maker disclosed a deal for EMcision, Limited, based in Montreal, Quebec.

The acquisition will expand the Boston Scientific Endoscopy portfolio to include the Habib EndoHPB probe, a novel endoscopic bipolar radiofrequency device, which coagulates tissue in the gastrointestinal tract. The Habib probe has been cleared by the U.S. FDA and received CE mark in the European Union.

Although financial terms for the deal were not disclosed, BSX said the acquisition is expected to be immaterial to earnings per share in 2018 on an adjusted and GAAP basis and accretive thereafter.

On March 21, the company announced its acquisition of NxThera Inc., a privately held medical device company based in Maple Grove, Minnesota. NxThera develops urologic applications using its Convective RF Water Vapor Thermal Therapy platform, with a focus on the treatment of benign prostatic hyperplasia (BPH).

The price for NxThera is $306 million, plus up to $100 million in milestone payments.

The acquisition will broaden Boston Scientific’s portfolio of products to treat pelvic health problems. NxThera will also spin out a startup as part of the deal, which will pursue regulatory approval of NxThera’s device as a treatment for prostate cancer. Boston Scientific, which was an investor in NxThera, will own the new company along with NxThera’s existing venture capital investors.

The deal is expected to close in the second quarter of 2018.